Disease · MONDO_0005466

hypersomnia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hypersomnia. Diseases, record MONDO_0005466. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005466

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hypersomnia; Open Targets
Open Targets ID: MONDO_0005466; Open Targets
Other names: hypersomnia (disease); Open Targets
NCI Thesaurus: C78346; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 8 drugs, from FDA; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PITOLISANT HYDROCHLORIDE	CHEMBL4164059	Small molecule	Approval	FDA	1	0	0	Drugs and targets
SOLRIAMFETOL HYDROCHLORIDE	CHEMBL4297212	Small molecule	Approval	FDA	1	0	0	Drugs and targets
SOLRIAMFETOL	CHEMBL4297620	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
MODAFINIL	CHEMBL1373	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CLARITHROMYCIN	CHEMBL1741	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUMAZENIL	CHEMBL407	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM OXYBATE	CHEMBL1200682	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets22

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABBR1	GABA-B receptor	1	GABA-B receptor agonist	Early phase 1	https://conductscience.org/library/genes/2550	Drugs and targets
GABBR2	GABA-B receptor	1	GABA-B receptor agonist	Early phase 1	https://conductscience.org/library/genes/9568	Drugs and targets
GABRA1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel allosteric antagonist	Phase 1/2	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel allosteric antagonist	Phase 1/2	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel allosteric antagonist	Phase 1/2	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel allosteric antagonist	Phase 1/2	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel allosteric antagonist	Phase 1/2	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel allosteric antagonist	Phase 1/2	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel allosteric antagonist	Phase 1/2	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel allosteric antagonist	Phase 1/2	https://conductscience.org/library/genes/2561	Drugs and targets

1 to 10 of 22

See all 22 targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03037203	A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness	Phase 2	66	2020-01-09	Excessive Sleepiness, Parkinson Disease	SOLRIAMFETOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT02806895	Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA	Phase 2	34	2020-06-16	Obstructive Sleep Apnea, Excessive Sleepiness	SOLRIAMFETOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT01146600	Clarithromycin for the Treatment of Hypersomnia	Phase 2	26	2014-06-12	Hypersomnia, Idiopathic Hypersomnia, Narcolepsy	CLARITHROMYCIN	Its record names the disease	ClinicalTrials.gov
NCT01183312	Flumazenil for the Treatment of Primary Hypersomnia	Phase 1/2	10	2013-03-27	Hypersomnia, Primary Hypersomnia, Idiopathic Hypersomnia, Narcolepsy Without Cataplexy	FLUMAZENIL	Its record names the disease	ClinicalTrials.gov
NCT06404086	RECOVER-SLEEP: Platform Protocol	Phase 2	830		Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance	MELATONIN, MODAFINIL, SOLRIAMFETOL	Its record names the disease	ClinicalTrials.gov
NCT06404112	RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)	Phase 2	469		Long COVID, Long COVID-19, Sleep Disturbance	MELATONIN	Its record names the disease	ClinicalTrials.gov
NCT06404099	RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)	Phase 2	361		Long COVID, Long COVID-19, Hypersomnia	MODAFINIL, SOLRIAMFETOL	Its record names the disease	ClinicalTrials.gov
NCT03626727	Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia	Early phase 1	0		Hypersomnia, Narcolepsy, Traumatic Brain Injury	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
JZP-110 vs Placebo: deaths from any cause	0 of 34	0 of 33	67	NCT02806895	Trial comparisons
JZP-110 vs Placebo: serious adverse events	0 of 34	0 of 33	67	NCT02806895	Trial comparisons
Clarithromycin vs Placebo: serious adverse events	0 of 22	0 of 20	42	NCT01146600	Trial comparisons
Sublingual Flumazenil vs Placebo: serious adverse events	0 of 10	0 of 10	20	NCT01183312	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36494591	DERIVED	1	PubMed
34191352	DERIVED	1	PubMed
34031871	DERIVED	1	PubMed
26094838	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005466

GET https://conductscience.org/api/diseases/v1/MONDO_0005466/targets?page=2

API reference For AI assistants